ERCC2 and female reproductive system neoplasm: The ERCC2 Lys751Gln polymorphism was found to increase the risk of gynecologic neoplasms(C vs A:OR 1.33, 95% CI 1.06-1.66;CC+CA vs AA:OR 1.33, 95% CI 1.11-1.59).